Characteristics of Successful Chief Medical Officers – Dr. Benit Maru : 2

The Emerging Biotech Leader
The Emerging Biotech Leader
Characteristics of Successful Chief Medical Officers - Dr. Benit Maru : 2
Loading
/

At biotech companies, things often evolve at light speed, and the natural tendency of a Chief Medical Officer (CMO) can be to try and manage every detail. But it’s a superhuman task, especially when powerful egos are in play.

This episode of The Emerging Biotech Leader features:

  • Dr. Ramin Farhood, Vice President of Medical Affairs, SSI Strategy
  • Kim Kushner, Senior VP, SSI Strategy
  • Dr. Benit Maru, Senior Vice President, Medical, SSI Strategy

The team recaps Episode 1’s conversation with Dr. Suku Nagendran – President of R&D and Chief Medical Officer (CMO) at Jaguar Gene Therapy, and former CMO at Avexis, a gene therapy start-up that delivered a life-saving drug for infants suffering from Spinal Muscular Atrophy Type 1 and achieved unicorn status – about the challenges and rewards of being a CMO.

Anyone in a leadership position or who aspires to leadership will benefit from listening to the conversation.

The Takeaway:

  • You can’t know everything, so surround yourself with a team that can help you achieve the end goal.
  • Courage counts. A CMO must take charge, speak their mind, and challenge others. And be able to take the hits.
  • Understand the dynamics of your leadership team. People on your team don’t always know each other: their backgrounds and strengths/weaknesses. This is especially true for start-ups that are rapidly growing and evolving.
  • Do the right thing for your patients and your company.

Diving deeper: 

A good CMO at a biotech company is like the conductor of a large orchestra; they must coordinate each section’s part in the symphony, as well as play to the

audience. The conductor can’t play every instrument, and as CMO, you need the self-awareness that you can’t do it all, so surround yourself with people with expertise in areas you don’t have. Strong leadership requires confidence, emotional maturity, and faith in the team around you.

To make the most of your resources, be resourceful. You can outsource specialized expertise to fill stopgap needs rather than onboarding new hires. Especially early on in the development process.

But perhaps the best quote is from Dr. Nagendran: ”I’m a nobody who became a somebody because of all the people around me.”

Challenges for CMOs

  1. It’s tough to admit you need help when trying to step up and take charge. This can be more difficult for younger “up-and-comers” than more experienced CMOs.
  2. Development timelines are truncated and complex; sometimes, expediency wins out.
  3. Investors are looking for ROI, and startups can’t afford to fail, so a CMO must construct a rationale that speaks to the CEO, board, and investors.
  4. You don’t always have time to consider the implications of your decisions, so you will make mistakes. But it’s better to make a few small mistakes than one big one.

More Episodes Like This

22-10-2024

Supercharging Biotechs: The Power of Strategic Board Engagement

This episode highlights key strategies for building trust, setting clear objectives, and managing board relationships.
07-10-2024

How Smart Risk Management Safeguards Your Biotech Venture

Risk management is a critical process that helps companies identify, prioritize, and mitigate potential issues affecting their operations, compliance, and financial stability. 
24-09-2024

Where Risk Meets Opportunity: Strategies for MedTech Success

Bijan emphasizes the balance between innovation and safety, noting that firms demonstrating significant benefits, especially in underserved areas, may find more regulatory flexibility. 
30-08-2024

Patients as Partners: A Winning Strategy for Drug Development – Laurie Smaldone-Alsup: 37

Early collaboration with patient advocacy groups can transform the development process, providing invaluable insights that shape everything from clinical trial design to regulatory strategies.
16-08-2024

Rare Diseases, Real Lives: Bridging Patient Needs and Drug Development – Dr. Edward M. Kaye : 36

While drug approval matters, the real aim is ensuring patients can access and use the treatments. This involves working with various healthcare systems and considering patient costs.
29-07-2024

Real-World Evidence and Putting Patients at the Center of Drug Development – Dr. Chantal van Gils : 35

Real-world evidence data is critical not just for regulatory approvals, but for convincing payers and patients of a product's value in the real world.

LET’S TALK

You don't have to go it alone! Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs.

This field is for validation purposes and should be left unchanged.